IDEXX Laboratories (NASDAQ:IDXX) Posts Quarterly Earnings Results, Beats Expectations By $0.25 EPS

IDEXX Laboratories (NASDAQ:IDXX) released its quarterly earnings data on Monday. The company reported $3.96 EPS for the quarter, beating the consensus estimate of $3.71 by $0.25, FiscalAI reports. The company had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.19 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.22 EPS.

Here are the key takeaways from IDEXX Laboratories’ conference call:

• IDEXX raised its 2026 outlook, increasing revenue guidance to $4.741 billion–$4.767 billion and EPS guidance to $14.96–$15.16. The company now expects 9.3%–10% organic revenue growth and 15%–16% comparable EPS growth.
• Third-quarter performance was strong, with 10% organic revenue growth, 11% organic growth in companion-animal diagnostics recurring revenue, and 22% comparable EPS growth. Growth was volume-led and supported by international expansion, new customers, premium instrument placements, and increased diagnostic utilization.
• Innovation momentum remains a major growth driver. IDEXX placed 5,780 premium instruments, including 1,904 inVue Dx analyzers, while expanding inVue Dx FNA availability, the Cancer Dx panel, Catalyst proBNP, and software capabilities.
• The company said inVue Dx placements are on track to exceed its 2026 target of 5,500 and its five-year goal of 20,000, with strong international demand and additional upside from FNA and future menu expansion.
• U.S. same-store clinical visits declined an estimated 1.8%, with muted puppy and kitten adoption trends and ongoing macroeconomic pressure. The CoVet acquisition is expected to dilute 2026 operating margin by approximately 30 basis points and EPS by about $0.13 per share in the near term, although management expects margin expansion as integration progresses.

IDEXX Laboratories Trading Up 21.8%

Shares of IDEXX Laboratories stock opened at $671.64 on Tuesday. The business has a fifty day simple moving average of $536.56 and a two-hundred day simple moving average of $573.88. IDEXX Laboratories has a 1 year low of $500.61 and a 1 year high of $769.98. The company has a market capitalization of $52.91 billion, a price-to-earnings ratio of 47.23 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.

IDEXX Laboratories News Roundup

Here are the key news stories impacting IDEXX Laboratories this week:

• Positive Sentiment: IDEXX reported third-quarter EPS of $3.96, above the $3.71 analyst consensus, while revenue increased 9.9% year over year to approximately $1.21 billion, exceeding expectations of $1.19 billion. IDEXX Laboratories earnings report
• Positive Sentiment: Recurring diagnostics revenue to veterinary practices rose about 11%, underscoring continued demand for IDEXX’s diagnostic instruments, consumables and services. Management raised its 2026 revenue and earnings guidance, signaling confidence that diagnostics growth can offset softer veterinary visits. IDEXX raises forecast
• Positive Sentiment: The strong results and upgraded outlook prompted favorable analyst commentary; Morgan Stanley reiterated its Buy rating and maintained an $805 price target, citing strong execution. Morgan Stanley reiterates Buy rating
• Neutral Sentiment: Investors are focused on whether IDEXX can sustain the accelerated diagnostics growth reflected in the higher guidance, particularly as the company operates at a premium valuation.
• Negative Sentiment: Some commentary cautioned that the improved profit forecast was not driven by stronger veterinary visit volumes, while the margin outlook remains a concern. Slower clinic traffic could limit broader demand and increase pressure on future growth. IDEXX margin outlook analysis

Insider Buying and Selling

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.79% of the stock is currently owned by company insiders.

Analyst Ratings Changes

IDXX has been the subject of a number of recent analyst reports. Leerink Partners cut their price target on shares of IDEXX Laboratories from $725.00 to $715.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Jefferies Financial Group lowered their price objective on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research note on Tuesday, October 20th. KeyCorp assumed coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They set a “sector weight” rating on the stock. BTIG Research dropped coverage on shares of IDEXX Laboratories in a report on Friday. They issued a “buy” rating on the stock. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Sunday, July 12th. Eight analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $727.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.